Meeting
2018 Genitourinary Cancers Symposium
Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study.
Authors
Daniel Peter Petrylak
Yale School of Medicine, New Haven, CT
Daniel Peter Petrylak , David C. Smith , Thomas W. Flaig , Jingsong Zhang , Srikala S. Sridhar , Joseph D. Ruether , Elizabeth R. Plimack , Jaime R. Merchan , David I. Quinn , Deepak Kilari , Sandy Srinivas , Joaquina Celebre Baranda , Joshua Michael Lang , Matthew I. Milowsky , Matt D. Galsky , Alexander I. Spira , Elaina M. Gartner , Chunzhang Wu , Amal Melhem-Bertrandt , Jonathan E. Rosenberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT02091999
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 431)
DOI
10.1200/JCO.2018.36.6_suppl.431
Abstract #
431
Poster Bd #
G2
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.
First Author: Christopher J. Hoimes
Poster
2023 ASCO Genitourinary Cancers Symposium
Updated outcomes in TROPHY-U-01 cohort 1, a phase 2 study of sacituzumab govitecan (SG) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI).
First Author: Scott T. Tagawa
Poster
2019 Genitourinary Cancers Symposium
EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).
First Author: Daniel Peter Petrylak
Poster
2019 Genitourinary Cancers Symposium
Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).
First Author: Jonathan E. Rosenberg